Equine/Horse Herpesvirus Type IV glycoprotein B antibody and antigen (recombinant protein)

Diagnostic anti-Equine/Horse Herpesvirus Type IV glycoprotein B antibodies pairs and antigen for animal health (animal Equine/Horse infectious disease respiratory disease) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Equine/Horse disease testing products collection >>


Product information

Catalog No. Description US $ Price (per mg)
GMP-VT-P138-Tg003-Ag01 Recombinant Equine/Horse Herpesvirus Type IV glycoprotein B protein $3090.00
GMP-VT-P138-Tg003-Ab01 Anti-Equine/Horse Herpesvirus Type IV glycoprotein B mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P138-Tg003-Ab02 Anti-Equine/Horse Herpesvirus Type IV glycoprotein B mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P138-Tg003-Ab03 Anti-Equine/Horse Herpesvirus Type IV glycoprotein B human monoclonal antibody (mAb) $3090.00
GMP-VT-P138-Tg003-Ab04 Anti-Equine/Horse Herpesvirus Type IV glycoprotein B human monoclonal antibody (mAb) $3090.00

Size: 1mg | 10mg | 100mg



Product Description

Cat No. GMP-VT-P138-Tg003-Ag01
Product Name Recombinant Equine/Horse Herpesvirus Type IV glycoprotein B protein
Pathogen Equine/Horse Herpesvirus Type IV
Expression platform E.coli
Isotypes Recombinant Antigen
Bioactivity validation Anti-Equine/Horse Herpesvirus Type IV glycoprotein B antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Equine/Horse Herpesvirus Type IV level test of animal Equine/Horse infectious disease with respiratory disease.
Tag His
Product description Recombinant Equine/Horse Herpesvirus Type IV glycoprotein B proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P138-Tg003-Ab01,GMP-VT-P138-Tg003-Ab02
Pathogen Equine/Horse Herpesvirus Type IV
Product Name Anti-Equine/Horse Herpesvirus Type IV glycoprotein B mouse monoclonal antibody (mAb)
Expression platform CHO
Isotypes Mouse IgG
Bioactivity validation Recombinant Equine/Horse Herpesvirus Type IV glycoprotein B antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine/Horse Herpesvirus Type IV antibodies in Equine/Horse Herpesvirus Type IV level test of animal Equine/Horse infectious disease with respiratory disease.
Product description Anti-Equine/Horse Herpesvirus Type IV glycoprotein B mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine/Horse Herpesvirus Type IV antibodies.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P138-Tg003-Ab03,GMP-VT-P138-Tg003-Ab04
Pathogen Equine/Horse Herpesvirus Type IV
Product Name Anti-Equine/Horse Herpesvirus Type IV glycoprotein B human monoclonal antibody (mAb)
Expression platform CHO
Isotypes Human lgG1
Bioactivity validation Recombinant Equine/Horse Herpesvirus Type IV glycoprotein B antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine/Horse Herpesvirus Type IV antibodies in Equine/Horse Herpesvirus Type IV level test of animal Equine/Horse infectious disease with respiratory disease.
Product description Anti-Equine/Horse Herpesvirus Type IV glycoprotein B mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Validation Data


    Click to get more Data / Case study about the product.



    Pathogen Information


    Equine herpesvirus type IV, also known as horse herpesvirus 4 or equine rhinopneumonitis virus, is a highly contagious pathogen of horses, donkeys, and zebras. It primarily affects the respiratory system, causing a range of illness severity from mild to severe, along with various other clinical manifestations such as abortion and neurological complications. In this article, we will discuss the classification, structure, hosts, clinical consequences, transmission, and diagnostic methods for EHV-4.

    Classification of EHV-4

    EHV-4 is classified as a virus belonging to the family Herpesviridae, which also includes several human herpesviruses, such as herpes simplex virus (HSV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), and varicella-zoster virus (VZV). These viruses share similar characteristics such as an icosahedral capsid, an envelope containing glycoproteins, and a double-stranded DNA genome. However, each virus has unique features that distinguish it from others in the family.

    Structure of EHV-4

    EHV-4 has an ordered structure consisting of an icosahedral capsid surrounded by an envelope. The capsid comprises 162 capsomeres arranged in a helical or icosahedral manner, encasing the viral genome. The envelope is derived from the host cell membrane and contains several glycoproteins, including gB, gC, and gD, which are essential for viral attachment and entry into host cells. Envelope proteins also play a crucial role in evading host immune responses.

    Hosts infected by EHV-4

    EHV-4 primarily infects horses, donkeys, and zebras. Infection can occur in all age groups, with yearlings and young horses being more susceptible. Horses can become infected through contact with contaminated items, such as feed, water, equipment, and personnel involved in handling infected horses. Additionally, EHV-4 can spread rapidly within a group of horses, especially in crowded or poorly ventilated environments.

    Clinical consequences of EHV-4 infection

    EHV-4 causes respiratory illness that ranges from mild to severe, depending on the animal's immune status and concurrent bacterial or viral infections. Clinical signs include fever, nasal discharge, coughing, lethargy, and loss of appetite. Some horses may develop secondary bacterial pneumonia due to weakened immunity caused by EHV-4 infection. The virus can also cause abortion in pregnant mares, particularly during the fifth to eighth month of gestation. In some cases, EHV-4 can lead to neurological disease, causing ataxia, paresis, paralysis, and even death.

    Transmission of EHV-4

    EHV-4 can spread through direct and indirect modes of transmission. Direct transmission occurs when healthy horses come in contact with respiratory secretions, such as nasal discharge, cough droplets, or saliva, from infected animals. Indirect transmission can occur when healthy horses come in contact with contaminated objects or fomites, such as surfaces, feed, water, equipment, or personnel. EHV-4 can survive outside the host for a few hours to several days, depending on environmental conditions.

    Diagnostic methods for EHV-4

    The diagnosis of EHV-4 relies on a combination of clinical signs, serology, virus isolation, and nucleic acid detection. Serologic assays, such as enzyme-linked immunosorbent assay (ELISA) and virus-neutralization test (VNT), measure the presence of EHV-4 antibodies in the serum of infected animals. However, these tests do not differentiate between vaccination and infection with EHV-4.

    Virus isolation involves the growth of EHV-4 in cell culture and detection of cytopathic effects or viral antigens. However, this method is time-consuming and requires a specialized laboratory setup. Nucleic acid detection methods, such as polymerase chain reaction (PCR) and reverse transcription PCR (RT-PCR), target specific genes encoding envelope glycoproteins, thymidine kinase, DNA polymerase, or ribonucleotide reductase. These methods have high sensitivity and specificity and can differentiate between vaccine strains and field strains. Furthermore, these tests can detect infection before the onset of clinical signs and during the latent phase of infection.

    In conclusion, EHV-4 is a significant pathogen of horses, donkeys, and zebras that can lead to respiratory, reproductive, and neurological complications. Early detection and appropriate management are crucial in controlling the spread of EHV-4 in susceptible populations. Veterinarians and horse owners should adopt preventive measures such as vaccination, quarantine, and biosecurity protocols to reduce the incidence of EHV-4 infection.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.